Peptide reimbursement is complex, with coverage varying significantly by insurance type, indication, and specific product. This reference covers reimbursement landscapes for major therapeutic peptides in the US market.
| Insurance Type | Peptide Coverage | Prior Auth Required | Key Restrictions |
|---|
| Commercial (employer) | Generally covered | Often yes | Step therapy, PA |
| Medicare Part B | Limited | Yes | Indication-specific |
| Medicare Part D | Covered (formulary) | Often yes | Tier placement |
| Medicaid | State-dependent | Yes | Varies by state |
| Tricare | Covered | Yes | Military-specific |
| VA | Covered | Yes | Formulary-based |
| Cash pay | N/A | No | Manufacturer programs |
| Product | Medicare | Commercial | Medicaid | Notes |
|---|
| Semaglutide (Ozempic) | Covered | Covered | State-dependent | T2D indication |
| Liraglutide (Victoza) | Covered | Covered | State-dependent | T2D indication |
| Dulaglutide (Trulicity) | Covered | Covered | State-dependent | T2D indication |
| Tirzepatide (Mounjaro) | Covered | Covered | State-dependent | T2D indication |
| Exenatide (Byetta) | Covered | Covered | State-dependent | Generic available |
| Product | Medicare | Commercial | Medicaid | Notes |
|---|
| Semaglutide (Wegovy) | Limited | Varies | Rarely | Obesity indication |
| Tirzepatide (Zepbound) | Limited | Varies | Rarely | Obesity indication |
| Liraglutide (Saxenda) | No | Varies | Rarely | Obesity indication |
Key Issue: Medicare does not cover anti-obesity medications under Part D. Commercial coverage varies widely by plan.
| Product | Medicare | Commercial | Medicaid | Notes |
|---|
| Insulin Glargine | Covered | Covered | Covered | Biosimilar available |
| Insulin Lispro | Covered | Covered | Covered | Biosimilar available |
| Insulin Aspart | Covered | Covered | Covered | Biosimilar available |
| Insulin Degludec | Covered | Covered | State-dependent | Premium pricing |
| Insulin Detemir | Covered | Covered | Covered | Generic available |
| Product | Medicare | Commercial | Medicaid | Notes |
|---|
| Tesamorelin (Egrifta) | Limited | Varies | Rarely | HIV lipodystrophy |
| Sermorelin | No | No | No | Not FDA-approved |
| Ipamorelin | No | No | No | Research chemical |
| CJC-1295 | No | No | No | Research chemical |
| Product | Indication | Medicare | Commercial | PA Required |
|---|
| Octreotide | Acromegaly | Covered | Covered | Yes |
| Leuprolide | Prostate cancer | Covered | Covered | Yes |
| Goserelin | Breast cancer | Covered | Covered | Yes |
| Vasopressin | Diabetes insipidus | Covered | Covered | Sometimes |
| Desmopressin | Bedwetting | Covered | Covered | Often |
| Criterion | Requirement |
|---|
| Diagnosis | T2D (ICD-10: E11.x) |
| HbA1c | ≥7.0% (some plans ≥7.5%) |
| Trial of metformin | 3+ months at max tolerated dose |
| BMI | ≥27 kg/m² (some plans require) |
| Contraindication check | No personal/family history of MTC, MEN2 |
| Prescriber | Endocrinologist or PCP (varies) |
| Criterion | Requirement |
|---|
| Diagnosis | Obesity (ICD-10: E66.x) |
| BMI | ≥30 kg/m² or ≥27 with comorbidity |
| Trial of lifestyle modification | 3–6 months documented |
| Trial of other weight loss agents | Phentermine, topiramate (some plans) |
| Exclusion of secondary causes | Thyroid, Cushing’s, etc. |
| Prescriber | Often requires specialist |
| Reason | Frequency | Appeal Strategy |
|---|
| Inadequate documentation | 40% | Resubmit with detailed records |
| Failed step therapy | 25% | Document contraindications |
| Not formulary preferred | 20% | Request formulary exception |
| BMI threshold not met | 10% | Include comorbidity documentation |
| Prescriber not specialist | 5% | Transfer to specialist |
| Company | Program | Eligibility | Benefit |
|---|
| Novo Nordisk | NovoCare | Income-based | Free/discounted medication |
| Eli Lilly | Lilly Cares | Income-based | Free medication |
| Sanofi | Sanofi Patient Connection | Income-based | Discounted medication |
| AstraZeneca | AZ&Me | Income-based | Free medication |
| Product | Program | Maximum Savings |
|---|
| Ozempic | Ozempic Savings Card | $150/month copay |
| Wegovy | Wegovy Savings Card | $0–25 copay |
| Mounjaro | Mounjaro Savings Card | $25 copay |
| Zepbound | Zepbound Savings Card | $25 copay |
| Trulicity | Trulicity Savings Card | $25 copay |
Note: Savings cards are not available for Medicare, Medicaid, or other government insurance.
| Entity Type | Discount | Eligibility |
|---|
| Federally Qualified Health Centers | 25–50% | 340B covered entities |
| Disproportionate Share Hospitals | 25–50% | 340B covered entities |
| Ryan White Clinics | 25–50% | 340B covered entities |
| Product | US Price | EU Price | UK Price | Canada Price |
|---|
| Ozempic (monthly) | $900–1,000 | $300–400 | $200–300 | $200–300 |
| Wegovy (monthly) | $1,300–1,500 | $400–500 | $300–400 | $300–400 |
| Mounjaro (monthly) | $1,000–1,100 | $350–450 | $250–350 | $250–350 |
| Trulicity (monthly) | $800–900 | $250–350 | $180–250 | $180–250 |
| Coverage | Part B | Part D |
|---|
| Administration | Physician-administered | Self-administered |
| Peptides covered | Limited (injectables in office) | Most self-administered |
| Deductible | 20% coinsurance | Plan-specific |
| Out-of-pocket max | None (traditional) | $2,000 (2025 cap) |
| Provision | Effective Date | Impact on Peptides |
|---|
| $2,000 OOP cap | 2025 | Limits out-of-pocket costs |
| Insulin $35/month cap | 2023 | Major cost reduction |
| Drug price negotiation | 2026 | Potential GLP-1 inclusion |
| Inflation penalty | 2023 | Limits price increases |
| Tier | Typical Copay | Peptide Examples |
|---|
| Tier 1 (Preferred generic) | $1–10 | Insulin (generic) |
| Tier 2 (Generic) | $10–25 | Insulin (branded generic) |
| Tier 3 (Preferred brand) | $25–50 | GLP-1 agonists (preferred) |
| Tier 4 (Non-preferred brand) | $50–100 | GLP-1 agonists (non-preferred) |
| Tier 5 (Specialty) | 25–33% coinsurance | GH secretagogues |
| State Category | GLP-1 Coverage (Obesity) | GLP-1 Coverage (Diabetes) |
|---|
| Expansion states | Sometimes | Generally covered |
| Non-expansion states | Rarely | Covered |
| Restrictive states | No | Limited |
| Requirement | Typical Standard |
|---|
| Diagnosis confirmation | ICD-10 code required |
| HbA1c documentation | ≥7.0% for diabetes |
| Metformin trial | 3+ months |
| Specialist referral | Endocrinologist preferred |
| Reauthorization | Every 6–12 months |
| Step | Timeframe | Action |
|---|
| Initial PA denial | Day 0 | Receive denial notice |
| Internal appeal | 30 days | Submit appeal to insurer |
| External review | 60 days | Independent review (if denied) |
| State insurance complaint | Varies | Regulatory complaint |
| Document | Purpose |
|---|
| Detailed medical records | Supports medical necessity |
| Prior treatment history | Documents failed alternatives |
| Lab results (HbA1c, BMI) | Meets clinical thresholds |
| Letter of medical necessity | Physician’s clinical rationale |
| Published guidelines | Supports standard of care |
- Diabetes indication has much broader coverage than obesity for GLP-1 agonists
- Prior authorization is nearly universal and requires documentation of clinical criteria
- Manufacturer PAPs and savings cards significantly reduce out-of-pocket costs for commercially insured patients
- Medicare coverage is evolving — the 35 cap are major changes
- International price differences are dramatic, with US prices 2–5× higher than EU/UK/Canada
- Appeals process is underutilized — many denials are overturned on appeal
- Oral formulations may improve access by enabling pharmacy (vs medical) benefit coverage
